Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

A newly developed vaccine against a group of viruses including SARS-CoV-2 is producing promising results in mice, part of the ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Findings indicate a sharp drop in immunity after Omicron infection, stressing the necessity for updated vaccines to enhance ...

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...

COVID-19 vaccination is linked to a transient decrease in hyperthyroidism risk but an increase in hypothyroidism risk over 12 ...

Infection with the SARS-CoV-2 Omicron variant confers weak, short-term protection against reinfection, compared with the much ...

Among adults in Ravensburg, Germany, financial incentives for COVID-19 vaccination did not result in significant changes to vaccine uptake and may have inadvertently lowered community vaccination ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

The study explores the potential of chitosan derivatives as novel inhibitors against the wild-type and emerging variants of ...

尽管如此，本研究为 65 岁以上老年人接种三种基于蛋白的含 XBB 疫苗后的中和抗体反应提供了重要证据，为优化老年人群疫苗接种策略、增强对新兴 SARS-CoV-2 变体的中和免疫力提供了关键信息。未来需进一步研究不同给药途径疫苗诱导的免疫特征、年龄对加强免疫后免疫力持久性的影响以及疫苗对新变体的效力等问题，以更好地应对新冠疫情，保障老年人群健康。